Results 61 to 70 of about 25,031 (288)

Ethical and legal issues in psychedelic harm reduction and integration therapy

Harm Reduction Journal, 2021
Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits.
Brian Pilecki, Jason B. Luoma, Geoff J. Bathje, Joseph Rhea, Vilmarie Fraguada Narloch   +4 more
doaj   +1 more source

Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice

Frontiers in Psychology, 2021
Psychedelic Harm Reduction and Integration (PHRI) is a transtheoretical and transdiagnostic clinical approach to working with patients who are using or considering using psychedelics in any context.
Ingmar Gorman, Ingmar Gorman, Ingmar Gorman, Ingmar Gorman, Elizabeth M. Nielson, Elizabeth M. Nielson, Elizabeth M. Nielson, Aja Molinar, Ksenia Cassidy, Ksenia Cassidy, Jonathan Sabbagh, Jonathan Sabbagh   +11 more
doaj   +1 more source

HYPERSCALING HOUSING: Venture Capital, Real Estate Start‐Ups and the Race to Build a Global Residential Brand

International Journal of Urban and Regional Research, EarlyView.
Abstract What happens when venture capitalists try to reinvent housing in their own image? Synonymous with the rise of Big Tech, venture capitalists (VCs) are asset managers that invest in early‐stage companies, pursuing aggressive growth and market domination. Since the 2008 financial crisis, VCs have poured huge sums into real estate start‐ups.
Tim White
wiley   +1 more source

Attitudes of European psychiatrists on psychedelics: a cross-sectional survey study

Scientific Reports
Research and public interest in psychedelic-assisted psychotherapy (PAP) are growing. This study investigated attitudes toward psychedelics among a diverse and multinational sample of psychiatrists currently working in Europe.
Marija Franka Žuljević, Darko Hren, Dawid Storman, Mariano Kaliterna, Darko Duplančić   +4 more
doaj   +1 more source

Psychedelics and neonihilism: connectedness in a meaningless world

Frontiers in Psychology, 2023
The resurgence of psychedelic research explicitly targets treating mental health conditions largely through psychedelics-assisted psychotherapy. Current theories about mechanisms of change in psychedelics-assisted psychotherapy focus on mystical ...
Patric Plesa, Rotem Petranker
doaj   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

The library is open: a scoping review on queer representation in psychedelic research

Frontiers in Public Health
The intersection of queer identity and psychedelics has not been thoroughly explored by the research community, historically or in the present day. With growing access to legal psychedelic therapies, it is essential that queer psychedelic experiences are
Amy Bartlett, Challian Christ, Bradford Martins, Kellen Saxberg, Terence H. W. Ching   +4 more
doaj   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source